SAN LUIS OBISPO, California – October 10, 2006 – FzioMed, Inc., a leader in surgical biomaterials, announced today the launch of www.laresse.com, the official website for the company’s new, ultra-smooth Laresse® dermal filler.
Laresse is the first of a family of dermal filler products based on FzioMed’s patented science. The company introduced Laresse in the United Kingdom this summer and will be presenting the product at the European Masters in Aesthetic and Anti-Aging Medicine conference, October 13-15, 2006 in Paris.
“Laresse represents a revolutionary advancement in dermal filler technology,“ said John Krelle, FzioMed President and Chief Operating Officer. “We are very excited to announce the opening of the Laresse.com website and the opportunity to communicate the features and benefits of our new product to the European aesthetic medical community.“
About Laresse Dermal Filler
Laresse is an ultra-smooth, clear gel for the correction of facial wrinkles and lines caused by sun exposure, aging and other factors. The easy-flowing gel is long lasting but non-permanent. Laresse is easier to inject through a fine gauge needle, is not made from bacterial or animal by-products, and contains no cross-linking chemicals. Laresse is available to medical practitioners in the European Union. Go to www.laresse.com for more information.
FzioMed is a privately held medical company developing and commercializing absorbable, surgical biomaterials based on the company’s patented Oxiplex science. Oxiplex is an innovative medical polymer technology with uses in a variety of specialties including orthopedics, spine, gynecology, general surgery and aesthetic surgery. FzioMed products include Oxiplex/SP, the leading adhesion barrier for spine surgery currently marketed outside of the United States, Oxiplex/AP adhesion barrier for gynecologic and general surgery, and Laresse cosmetic dermal filler. FzioMed products are for investigational use only in the United States.
FzioMed®, Oxiplex® and Laresse® are registered trademarks of FzioMed, Inc.